Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
|Slideshows|December 6, 2014
Are We Overtreating DCIS?
Author(s)Laura J. Esserman, MD, MBA
With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.
Advertisement
Advertisement
Related to this article
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
SurVaxM, a cancer vaccine, missed statistical significance for overall survival in patients with newly diagnosed glioblastoma in the SURVIVE trial.
Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
3
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5